HYDERABAD, India, July 24, 2018 /PRNewswire/ --
Granules India Ltd., a growing pharmaceutical manufacturing company,announced today its financial results for the first quarter ended 30th June 2018.
CONSOLIDATED FINANCIALS Q1 FY'19 TOTAL INCOME INR 468 Crs. EBITDA
The Company reported a standalone Total Income during the quarter of INR 458 Crs. EBITDA for the quarter was INR 88 Crs. and PAT stood at INR 40 Cr. respectively.
The Company's Board of Directors has proposed a final dividend of 25 paise / share of face value of Rs. 1 each.
"The first quarter of the current financial year started on a positive note. We saw our total income increase by 21% compared to the same period of previous fiscal. There was also a sequential growth in margin profiles despite the continuing raw material pricing pressures. We have worked towards mitigating this partially to the extent that is in our control. A new supplier has been added for a key raw material and we are simultaneously scouting for newer sources of raw materials. Our belief in the potential of our Joint Ventures has been validated again by their encouraging contribution in achieving 41% growth in the consolidated profit of the Company over the same quarter of previous financial year. Additionally, during this quarter, we have further strengthened our product portfolio by introducing new products. I am happy to share that generic Methylergonovine tablets (Methergine) was launched in partnership with Hikma Pharmaceuticals Plc. by Granules Pharmaceuticals, Inc., the wholly owned subsidiary of Granules India Ltd. This is the first product commercialised from our R&D and manufacturing facility in Virginia," said Mr. Krishna Prasad Chigurupati, Chairman & Managing Director, Granules India Limited.
About Granules India Ltd. (BSE: 532482) (NSE: GRANULES)
Granules India is a growing pharmaceutical manufacturing company with best in class facilities and is committed to operational excellence, quality and customer service. The Company produces Finished Dosages (FDs), Pharmaceutical Formulation Intermediates (PFIs) and Active Pharmaceutical Ingredients (APIs) which gives the customers flexibility and choice. Granules support customers with unique value, extensive product range, and proactive solutions. The Company's global presence extends to over 250 customers in 60 countries through offices in India, U.S., and U.K.
Media Contact: Hari Prasad Gogikar email@example.com +91-9618883774 Concept Public Relations India Limited
Subscribe to our Free Newsletters!
Mastocytosis is a rare condition marked by accumulation of mast cells under the skin and various ...
Lusutrombopag is used to treat abnormally low platelet counts (thrombocytopenia) in adult patients ...
Stereotypic movement disorder (SMD) is a motor disorder, associated with neurodevelopmental ...View All